Different Effect of Dienogest on Endometrium Mesenchymal Stem Cells Derived from Healthy and Endometriosis Tissues

Autor: Uzelli Şimşek H; Department of Obstetrics and Gynecology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye, Şimşek T; Department of General Surgery, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye, Duruksu G; Center for Stem Cell and Gene Therapies Research and Practice, Kocaeli University, Kocaeli, Türkiye; Department of Histology and Embryology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye, Furat Rençber S; Center for Stem Cell and Gene Therapies Research and Practice, Kocaeli University, Kocaeli, Türkiye; Department of Histology and Embryology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye, Yazır Y; Center for Stem Cell and Gene Therapies Research and Practice, Kocaeli University, Kocaeli, Türkiye; Department of Histology and Embryology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
Jazyk: angličtina
Zdroj: Balkan medical journal [Balkan Med J] 2024 Oct 31; Vol. 41 (6), pp. 484-490. Date of Electronic Publication: 2024 Sep 18.
DOI: 10.4274/balkanmedj.galenos.2024.2024-6-95
Abstrakt: Background: Endometriosis (EM) is an inflammatory condition in which the endometrium is observed to develop outside the uterine cavity. Endometrium has conventionally been recognized as a rich source of endometrial mesenchymal stem cells (E-MSCs). The influence of dienogest, a medication frequently prescribed for EM, on E-MSCs has not been extensively investigated.
Aims: To explore effects of dienogest on the E-MSCs derived from healthy (E-MSCs-control) and diseased (E-MSCs-endometriosis) endometrial tissue samples in vitro.
Study Design: In vitro study.
Methods: We collected samples from healthy and diseased endometrial tissues. E-MSCs were derived from both healthy and EM tissues. The effect of dienogest (VISANNE) on E-MSCs was assessed by examining cell proliferation, telomerase activity, cell migration, and estrogen secretion levels after the isolation and characterization of E-MSCs.
Results: We discovered that cellular proliferation rate was higher in the E-MSCs derived from EM tissues compared to those derived from healthy tissue. The proliferation rate and telomerase activity were both suppressed by dienogest treatment, particularly in E-MSCs-endometriosis. The drug treatment also resulted in a decrease in the migration capacity of E-MSCs-endometriosis, from 60.4% to 59.2%. The expression of CXCL12, Ki67, and beta-catenin was analyzed in both E-MSCs-endometriosis and E-MSCs-control. The CXCL12 and Ki67 expressions were quite elevated in the E-MSCs-endometriosis without drug treatment compared to the E-MSCs-control. Following the treatment, these levels declined drastically to the levels close to E-MSCs-control. Similarly, this decrease in gene expression was accompanied by a decrease in estrogen secretion into the medium.
Conclusion: This research demonstrates that dienogest exerts a substantial impact on both stromal and stem cells, as it effectively controls the disease by reversing EM markers, despite the absence of progesterone receptors on endometrial stem cells.
Competing Interests: Conflict of Interest: The authors declare that they have no conflict of interest.
Databáze: MEDLINE
Externí odkaz: